is now

Please update your bookmarks and favorites.
You will be taken to the new site in a few seconds.

Inform Diagnostics News

For media inquiries, contact Joy Jennings:
email joy.jennings [at] informdx [dot] com
office 214.596.7055.

For all other requests (not members of the media), please use the Contact Us form.


Miraca Life Sciences Announces Company Name Change to Inform Diagnostics

IRVING, Texas, January 8, 2018 — Miraca Life Sciences announced today that it has changed its name to Inform Diagnostics effective immediately. The company was acquired in November by Avista Capital Partners from previous owner Miraca Holdings. The name Inform Diagnostics and new logo were chosen to highlight the company’s focus on providing pathology and diagnostic capabilities that together help [...] Read More »

Avista Capital Partners Completes Acquisition of Miraca Life Sciences

IRVING, Texas and NEW YORK, Nov. 20, 2017 — Avista Capital Partners (“Avista”), a leading private equity firm, today announced the completion of its acquisition of Miraca Life Sciences (“MLS” or the “Company”) from Miraca Holdings Inc.

Continue reading the press release at the Avista website.

Read More »

Renflexis™ is Latest Addition to Therapeutic Drug Monitoring by Miraca Life Sciences

IRVING, Texas, October 16, 2017 — Miraca Life Sciences, the largest U.S. independent anatomic pathology laboratory, continues to expand in clinical pathology: its InformTx™ therapeutic drug monitoring (TDM) has begun the validation process for Renflexis™ (infliximab-abda), a biosimilar of Remicade® (infliximab). Testing will be commercially available in early November. Since launching the InformTx service in June 2016, Miraca Life Sciences [...] Read More »

Biocept and Miraca Life Sciences Enter Into Marketing Agreement to Expand Target Selector Testing in the United States

MLS to market Biocept’s proprietary liquid biopsy testing platform in key sales territories, with potential to expand the agreement in the future

SAN DIEGO (October 3, 2017) – Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, announces that it has entered [...] Read More »

Avista Capital Partners to Acquire Miraca Life Sciences

IRVING, TX, NEW YORK, NY, and TOKYO, September 22, 2017 – Avista Capital Partners (“Avista”), a leading private equity firm, and Miraca Holdings Inc. (“MHD”) announced today that Avista has signed a definitive agreement to acquire Miraca Life Sciences (“MLS” or “the Company”), a wholly-owned subsidiary of Miraca Holdings Inc. Continue reading press release

Read More »

Miraca Research News: Philips receives FDA clearance to market Philips IntelliSite Pathology Solution for primary diagnostic use in the US

Pathologists at Miraca Life Sciences contributed significantly in the development of a new product from Philips, the IntelliSite Pathology Solution. As one of four clinical study sites, Miraca Life Sciences participated in “one of the largest studies ever conducted to directly compare the use of digital pathology to optical microscopes.” At Miraca, participation in the Philips study was a project of Miraca [...] Read More »

Ten Research Projects from Miraca Life Sciences Accepted for DDW Conference

IRVING, Texas, April 12, 2017 — Ten research projects from the GI pathologists at Miraca Life Sciences, the nation’s largest independent anatomic pathology lab, have been accepted for presentation at the Digestive Disease Week® conference (DDW), which will be held May 6–9 in Chicago. DDW is the world’s largest gathering of physicians, researchers and industry in the fields of gastroenterology, [...] Read More »

Simponi® is Sixth Drug in InformTx™ Therapeutic Drug Monitoring Service from Miraca Life Sciences

IRVING, Texas, March 28, 2017 — Miraca Life Sciences, the largest U.S. independent anatomic pathology laboratory, continues to expand its InformTx™ therapeutic drug monitoring (TDM) capabilities, now testing for Simponi (golimumab) as well as patient-developed antibodies to Simponi. This is the first TDM assay available in the United States for Simponi. With this addition, Miraca Life Sciences now performs TDM [...] Read More »

Stelara® Now Available for Therapeutic Drug Monitoring from Miraca Life Sciences

IRVING, Texas, December 1, 2016 — Miraca Life Sciences, the largest U.S. independent anatomic pathology lab, has expanded its InformTx™ therapeutic drug monitoring service for drugs that treat inflammatory bowel disease (IBD) with the addition of Stelara (ustekinumab).

Miraca Life Sciences continues to perform therapeutic drug monitoring (TDM) for Remicade® (infliximab), Humira® (adalimumab), Cimzia® (Certolizumab pegol) and Entyvio® (vedolizumab). Since [...] Read More »

Ten Research Projects from Miraca Life Sciences Accepted for ACG Conference

IRVING, Texas, August 10, 2016 — Ten research projects from the GI pathologists at Miraca Life Sciences, the nation’s largest independent anatomic pathology lab, have been accepted for presentation at the Annual Meeting of the American College of Gastroenterology (ACG), which will be held October 14–19 in Las Vegas.

Authors from Miraca Life Sciences are linked below to their profile [...] Read More »

Dermatology


See why Miraca Life Sciences' dermatopathology service is growing with consultations on biopsies from over 275,000 patients annually.

learn more

Gastroenterology


Explore why Miraca Life Sciences is the largest outpatient gastrointestinal pathology facility in the nation.

learn more

Hematology


Learn how Miraca Life Sciences delivers the highest quality expertise in blood and bone marrow diagnostics.

learn more

Urology


Miraca Life Sciences Urologic Pathology Services

Discover how Miraca Life Sciences' urologic pathology experts focus on service and diagnostic excellence.

learn more